2. Academic Validation
  3. ALK Inhibitors for Treating Cancer, Blood, and Kidney Diseases

ALK Inhibitors for Treating Cancer, Blood, and Kidney Diseases

  • ACS Med Chem Lett. 2022 Sep 7;13(10):1539-1541. doi: 10.1021/acsmedchemlett.2c00388.
Robert B Kargbo 1
Affiliations

Affiliation

  • 1 Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
PMID: 36267131 DOI: 10.1021/acsmedchemlett.2c00388
Abstract

Cancers that traditionally have been resistant to Apoptosis via chemical- or radiation-based therapies may respond when the treatments are combined with ALK-5 inhibition. Disclosures in this Patent Highlight provide inhibitors of activin-receptor-like kinases such as ALK-5, compositions and methods for increasing red blood cell or Hemoglobin levels, and activin antagonists to treat, prevent, or reduce the progression rate or severity of kidney disease.

Figures
Products